2. Signaling Pathways
  3. Apoptosis
  4. DAPK

DAPK

Death associated protein kinase

DAPK

Related Products

PDF 0.06 MB

DAPK (Death-associated protein kinase) is the founding member of a newly classified family of Ser/Thr kinases, whose members not only possess significant homology in their catalytic domains, but also share cell death-associated functions. The realization that DAPk is a tumor suppressor gene, whose expression is lost in multiple tumor types, has spurred a flurry of interest in the kinase family and produced an impressive body of literature concerning its function, regulation, and connection to disease. The DAPk family has been linked to several cell death-related signaling pathways, and functions other than cell death have also been proposed.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15513
    TC-DAPK 6
    		Inhibitor
    TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor (IC50=69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 μM ATP).
    TC-DAPK 6
  • HY-15847
    HS38
    		Inhibitor 99.91%
    HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders.
    HS38
  • HY-102069
    3MB-PP1
    		Inhibitor 99.66%
    3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division.
    3MB-PP1
  • HY-122629
    DRAK2-IN-1
    		Inhibitor 99.93%
    DRAK2-IN-1, compound 16, is a potent, selective and ATP-competitive DRAK2 inhibitor with IC50and Kivalues of 3 nM and 0.26 nM, respectively. DRAK2-IN-1 also has inbitory effect on DRAK1 (IC50=51 nM).
    DRAK2-IN-1
  • HY-112056
    DIM-C-pPhCO2Me
    		Inhibitor 99.47%
    DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research.
    DIM-C-pPhCO2Me
  • HY-125404
    DAPK-IN-1
    		Inhibitor
    DAPK-IN-1 is a DAPK1 and DAPK3 inhibitor. DAPK-IN-1 is applicable to research related to cerebral infarction, myocardial infarction and renal failure.
    DAPK-IN-1
  • HY-184326
    DRAK2-IN-2
    		Inhibitor
    DRAK2-IN-2 is a selective DRAK2 inhibitor with an IC50 value of 198.5 nM. DRAK2-IN-2 inhibits DRAK2-mediated phosphorylation of ULK1 at the Ser56 site. DRAK2-IN-2 enhances insulin secretion, increases mitochondrial membrane potential, alleviates Palmitic acid (HY-N0830)-induced mitochondrial membrane potential damage and Apoptosis, and improves glucose tolerance in vivo. DRAK2-IN-2 can be used for the research of type 2 diabetes.
    DRAK2-IN-2
  • HY-186224
    GW296115
    		Inhibitor
    GW296115 is a multi-target inhibitor with the following IC50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3. GW296115 downregulates the phosphorylation of S317 site on ULK1 and S351 site on P62, which are AMPK substrates driven by BRSK2. GW296115 does not alter the phosphorylation level of AMPK at T172, reduces nutrient deprivation-mediated Autophagy and autophagosome formation, and enhances Apoptosis. GW296115 exhibits anticancer activity against triple-negative breast cancer. GW296115 is applicable for breast cancer-related research.
    GW296115
  • HY-117364
    HS148
    		Inhibitor 98.00%
    HS148 (compound 22) is a selective DAPK3 inhibitor with an Ki value of 119 nM.
    HS148
  • HY-156350
    SGC-STK17B-1
    		Inhibitor 98.53%
    SGC-STK17B-1, a chemical probe, is an ATP-competitive and selective STK17B (a member of DAPK family) inhibitor (IC50: 34 nM, KD: 5.6 nM).
    SGC-STK17B-1
  • HY-145293
    TNIK-IN-3
    		Inhibitor 99.79%
    TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC50 of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC50=0.030 μM), Flt1 (IC50=0.191 μM) and DRAK1 (IC50=0.411 μM). TNIK-IN-3 can be used for the research of colorectal cancer.
    TNIK-IN-3
  • HY-163626A
    STK17A/B-IN-1 hydrochloride
    		Inhibitor
    STK17A/B-IN-1 hydrochloride is an orally active, potent and selective STK17A/B inhibitor with an IC50 value of 23 nM for STK17A. STK17A/B-IN-1 hydrochloride can be used in tumor research.
    STK17A/B-IN-1 hydrochloride
  • HY-169109
    DAPK1-IN-1
    		Inhibitor 99.80%
    DAPK1-IN-1 (compound 10) is a death-associated protein kinase 1 (DAPK1) inhibitor with a Kd value of 0.63 μM. DAPK1-IN-1 can be used in Alzheimer’s disease research.
    DAPK1-IN-1
  • HY-149006
    CK156
    		Inhibitor 99.60%
    CK156, a chemical probe, is a highly selective death-associated protein kinase (DAPK) inhibitor with IC50s of 182 nM,34 μM, and 39 μM in the DRAK1 NanoBRET assay for DRAK1, CK2a1, and CK2a2, respectively. CK156 can be used for the research of autoimmune and inflammatory diseases.
    CK156
  • HY-120040
    HS94
    		Inhibitor 98.92%
    HS94 is a selective DAPK3 inhibitor. HS94 can be used for research of hypertension.
    HS94
  • HY-153595
    DAPK-IN-2
    		Inhibitor 98.02%
    DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases.
    DAPK-IN-2
  • HY-123983
    HS56
    		Inhibitor 99.6%
    HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension.
    HS56
  • HY-163626
    STK17A/B-IN-1
    		Inhibitor
    STK17A/B-IN-1 (compound 9) is an orally active, potent, and selective STK17A/B inhibitor with an IC50 of 23 nM against STK17A. STK17A/B-IN-1 can be used for study of cancer.
    STK17A/B-IN-1
  • HY-152954
    DRAK1/2-IN-1
    		Inhibitor
    DRAK1/2-IN-1 (compound 10e) is an active dual DRAK1 and DRAK2 inhibitor with Kd values of 1 μM and 6 μM, respectively.
    DRAK1/2-IN-1
  • HY-175477
    UNC9750
    		Inhibitor
    UNC9750 is an inositol phosphate multikinase (IPMK) inhibitor with IC50 values ​​of 31.6 and 374 nM for IPMK and IP6K2, respectively.. UNC9750 inhibits cellular accumulation of InsP5, the direct product of IPMK kinase activity, while having no effect on either InsP6 or InsP7 levels. UNC9750 has ≥ 75% inhibition of four kinases (DAPK1, DYRK1B, PDGFR, and KDR). UNC9750 can be used for the study of glioblastoma.
    UNC9750
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity